Division of Gastroenterology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Leonard Davis Institute for Health Economics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Am J Gastroenterol. 2024 Aug 1;119(8):1616-1623. doi: 10.14309/ajg.0000000000002755. Epub 2024 Mar 13.
There is substantial variability in patient outcomes for gastrointestinal bleeding (GIB) across hospitals. This study aimed to identify hospital factors associated with GIB outcomes.
This was a retrospective cohort study of Medicare fee-for-service beneficiaries hospitalized for GIB from 2016 to 2018. These data were merged with the American Hospital Association Annual Survey data to incorporate hospital characteristics. We used generalized linear mixed-effect models to estimate the effect of hospital-level characteristics on patient outcomes after adjusting for patient risk factors including anticoagulant and antiplatelet use, recent GIB, and comorbidities. The primary outcome was 30-day mortality, and secondary outcomes included length of stay and a composite outcome of 30-day readmission or mortality.
Factors associated with improved GIB 30-day mortality included large hospital size (defined as beds >400, odds ratio [OR] 0.93, 95% confidence interval [CI] 0.90-0.97), greater case volume (OR 0.97, 95% CI 0.96-0.98), increased resident and nurse staffing (OR 0.88, 95% CI 0.83-0.94), and blood donor center designation (OR 0.93, 95% CI 0.88-0.99). Patients treated at a hospital with multiple advanced capabilities, such as availability of advanced endoscopy, advanced intensive care unit (ICU) capabilities (both a medical-surgical ICU and cardiac ICU), blood donor center, and liver transplant center, had a 22% reduction in 30-day mortality risk, compared with those hospitalized in a hospital with none of these services (OR 0.78, 95% CI 0.68-0.91). However, length of stay increased with additional services.
Patients hospitalized for GIB at hospitals with multiple advanced specialized capabilities have lower mortality but longer lengths of stay. Further research should examine the processes of care linked to these services that contribute to improved mortality in GIB.
在不同医院,胃肠道出血(GIB)患者的预后存在显著差异。本研究旨在确定与 GIB 结局相关的医院因素。
这是一项回顾性队列研究,纳入了 2016 年至 2018 年因 GIB 住院的 Medicare 按服务收费受益人的数据。这些数据与美国医院协会年度调查数据合并,以纳入医院特征。我们使用广义线性混合效应模型,在调整了患者风险因素(包括抗凝和抗血小板药物使用、近期 GIB 和合并症)后,估计医院水平特征对患者结局的影响。主要结局是 30 天死亡率,次要结局包括住院时间和 30 天内再入院或死亡的复合结局。
与 GIB 30 天死亡率降低相关的因素包括医院规模较大(定义为床位>400 张,比值比 [OR] 0.93,95%置信区间 [CI] 0.90-0.97)、较高的病例量(OR 0.97,95% CI 0.96-0.98)、增加住院医生和护士人员配备(OR 0.88,95% CI 0.83-0.94)和血液捐献中心指定(OR 0.93,95% CI 0.88-0.99)。与在没有这些服务的医院(OR 0.78,95% CI 0.68-0.91)相比,在具有多种高级专业能力(如先进内镜可用性、先进重症监护病房 [ICU] 能力(普通外科 ICU 和心脏 ICU)、血液捐献中心和肝移植中心)的医院接受治疗的患者 30 天死亡率降低了 22%。然而,随着服务的增加,住院时间也会延长。
在具有多种先进专业能力的医院接受 GIB 治疗的患者死亡率较低,但住院时间较长。进一步的研究应该检查与这些服务相关的护理流程,这些流程有助于改善 GIB 的死亡率。